NewLimit
San Francisco, United States · Biotechnology · 51 employees
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and
Funding history
- Funding Round — $435.0M — Jun 2026
- Funding Round — $45.0M — Oct 2025
- Funding Round — $129.8M — May 2025
- Series series b — $130.0M — May 2025
- Funding Round — $72.2M — Jan 2025
Recent signals
- Jun 02, 2026: Raised $435.0M
- Oct 21, 2025: Raised $45.0M
- May 15, 2025: Raised $129.8M
- May 07, 2025: Raised $130.0M in Series series b
- Jan 07, 2025: Raised $72.2M
- May 17, 2023: Raised $72.2M
- May 16, 2023: Raised $40.0M
See plans & pricing → Track NewLimit’s funding, hiring, and signals — with verified contacts — on Fundz.